Drug intelligence / Profile preview

SBI-993

Development stage: Preclinical
Lead developer: Sanford Burnham Prebys Medical Discovery Institute
Modality: Small Molecules
Administration: Subcutaneous

Overview

SBI-993 is a small molecule inhibitor of the transcription factor Carbohydrate responsive element binding protein (ChREBP), also known as MLXIPL. In hepatocellular carcinoma (HCC), ChREBP acts as an oncogene by regulating the PI3K regulatory subunit p85α, which sustains PI3K/AKT signaling, and by rerouting metabolic fluxes to support cell anabolism. SBI-993 has shown the ability to suppress in vivo HCC tumor growth in preclinical models, highlighting its potential as a targeted therapy for liver cancer.

Targets

MLXIP (MondoA / MLXIP)MLXIPL (ChREBP / MLXIPL)

Beyond the preview

Go deeper on SBI-993.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBI-993.

Explore the full profile